Current treatments for bone metastatic prostate cancer (PC), which target androgen synthesis (androgen deprivation therapy, ADT) and/or androgen receptor (AR) signaling, along with taxanes, provide only temporary relief [1], highlighting the need for more effective treatments. The gene discussed is AR; the disease is pachyonychia congenita.